NCT01028820View on ClinicalTrials.gov

FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders

PHASE4CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Autism Spectrum Disorder

Interventions

DRUG

Aripiprazole

8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily

Trial Locations (2)

27599

University of North Carolina, Chapel Hill

27705

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

Duke University

All Listed Sponsors

collaborator

Duke University

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT01028820 - FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter